Achieving non-surgical preventions for inherited BRCA cancer – it is time!
Date: Wednesday, May 9th Time: 11:45 - 13:15 (Lunch will be provided) Location: Centre Mont-Royal (Room TBA at registration)
Moderator: Lawrence Brody, PhD. Director, Genomics and Society; National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
Today, preventive surgeries are the principal option to reduce cancer risk for carriers of an inherited BRCA gene mutation, however, these interventions are invasive, life-altering and associated with adverse consequences. Therefore, non-surgical options such as pre-cancer vaccines are urgently needed. Traditionally, cancer prevention has not been a priority for medical research. An expert panel and the participants of this symposium will discuss how to overcome the historical hurdles to cancer prevention, focus on opportunities for achieving non-surgical prevention of BRCA cancer, and review the recent progress of the global HeritX Initiative to prevent inherited BRCA cancers.
About HeritX: The nonprofit research and development organization HeritX was launched in 2015. This initiative is the first comprehensive effort to develop non-surgical preventive therapies for inherited BRCA cancers. HeritX currently collaborates with 15 scientific centers worldwide on research aimed at producing non-surgical BRCA cancer preventions as fast as possible and available to all. www.Heritx.org
Optimising BRCA1/2 mutation testing criteria and the clinical implications; perspectives from Canadian and international institutions
Date: Thursday, May 10th Time: 11:45 - 13:15 Location: Mont-Royal room, Centre Mont-Royal
Eligibility criteria for BRCA1/2 testing in patients with breast cancer; The Canadian experience Raymond Kim, MD / PhD, FRCPC, FCCMG, FACMG Medical Geneticist, Assistant Professor, Department of Medicine, University of Toronto, Toronto, Canada
Mainstreaming and the impact on patient outcomes in ovarian and breast cancer: learnings from The Royal Marsden model Angela George, MB, ChB, FRACP, MD Medical Oncologist, Consultant in Oncogenetics, Clinical Lead - Cancer Genetics Unit, The Royal Marsden, NHS Foundation Trust, London, UK
Outline how BRCA1/2 mutation testing criteria varies across Canada, for both breast and ovarian cancer, including traditional genetics referral routes and recent developments in the ovarian cancer space
Discuss Canadian initiatives underway to streamline the BRCA1/2 testing process, including an overview of tumour-based testing from a genetics perspective
Summarise the criteria used, and data collected from The Royal Marsden, demonstrating how mainstreaming for breast cancer is taking place alongside ovarian cancer in the UK and internationally
Illustrate the importance of ‘the right’ criteria in identifying increased numbers of patients eligible for BRCA1/2 mutation testing in the HER-2 breast cancer population
Apply learnings from The Royal Marsden mainstreaming and tumour testing model and other international initiatives to Canadian methods
Review the data available in breast and ovarian cancer to assess patient treatment options, from a multidisciplinary team perspective
Angela George, MB, ChB, FRACP, MD Medical Oncologist, Consultant in Oncogenetics, Clinical Lead - Cancer Genetics Unit, The Royal Marsden, NHS Foundation Trust, London, UK
Dr Angela George is a Consultant in Oncogenetics, and Clinical Lead for the Cancer Genetics Unit. She initially trained in Medical Oncology in New Zealand, with a particular interest in gynaecological and breast cancers. She then began research into underlying genetic causes of ovarian cancer and led the implementation of the Mainstreaming Cancer Genetics programme. This has greatly expanded access to genetic testing for patients with ovarian and breast cancer.
She continues her research interests in ovarian cancer; and also works as a medical oncologist within the gynaecology unit. She has a particular interest in the use of genetic information to guide treatment choice.
Raymond Kim, MD / PhD, FRCPC, FCCMG, FACMG Medical Geneticist, Assistant Professor, Department of Medicine, University of Toronto, Toronto, Canada
Raymond Kim received his MD / PhD from the University of Toronto with Dr. Tak W. Mak in Medical Biophysics. He then completed a residency in Internal Medicine, followed by a fellowship in Medical Genetics at The Hospital for Sick Children. He is involved in the diagnosis of patients with hereditary breast and ovarian cancer and Lynch syndrome. He has a large practice of patients with rare cancer syndromes such as Li-Fraumeni syndrome, DICER1, Neurofibromatosis, Von Hippel Lindau and Cowden syndrome. His clinical interests lie in transition of care, complex multi-disciplinary care, and genomic medicine.